USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
03 Aug 2022 | 02:45 PM GMT

Scalable Business Models for Digital Health in Oncology

Anchored by:

Andrew Norden
Chief Medical Officer
ONCOHEALTH
Lynda Chin
Co-Founder, President and CEO
APRICITY

Participants:

Andrew Norden Chief Medical OfficerOncoHealth
Andrew Norden
Chief Medical OfficerOncoHealth
Lynda Chin Co-Founder, President and CEOApricity
Lynda Chin
Co-Founder, President and CEOApricity
Ashutosh Malhotra Director Digital Health Strategy & PartnersDaiichi Sankyo
Ashutosh Malhotra
Director Digital Health Strategy & PartnersDaiichi Sankyo
Cathy Zaremba Director, Product MarketingBrightInsight
Cathy Zaremba
Director, Product MarketingBrightInsight
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Francesca Wuttke Founder & CEOnen Health
Francesca Wuttke
Founder & CEOnen Health
Kelly McCabe Co-Founder & CEOPerci Health
Kelly McCabe
Co-Founder & CEOPerci Health
Ricardo C. Berrios Co-Founder & CEOAdhera Health, Inc.
Ricardo C. Berrios
Co-Founder & CEOAdhera Health, Inc.
Richard Secker-Johnson Associate PrincipalZS Associates
Richard Secker-Johnson
Associate PrincipalZS Associates

About this Meeting

The investment case for digital health and oncology is straightforward - apply digital innovation to one of the most prevalent diseases worldwide, improve millions of patients' lives, and reap the rewards. While the opportunity may be straightforward, the scalability of these solutions is not.  

The marriage of digital health and oncology is still nascent, with companies figuring out the best approach. A key topic for our community is building sustainable business models and getting over the adoption hurdle to build to scale.  

In this meeting we will break down the pro’s and con’s of the different options to get the right business model for Oncology-focused digital health companies. Join to discuss:   
  • For entrepreneurs, it is important to look at as many options as possible, so flexibility in approach may be required. How can companies streamline their decision making and look at the ability to pivot between, or potentially combine, different business  models? Does having hybrid business models slow down scalability?  
  • While some business models and pilots work in the short term to show early results and initial revenue, they may not be the right model for the scaling phase. How can companies think about model scalability from early on? 
  • Scaling within a country can be challenging, but scaling across countries is even more complex. What may work in one country, may not in the neighbouring country. What approach should companies take to ensure efficient scalability of their product across geographies? 
  • What are the factors that determine the most scalable business model for a digital health company in oncology? E.g. type of cancer, type of product, competitors, available resources, evidence data, etc. 
  • While there are direct-to-consumer opportunities within oncology, most companies have taken an approach that requires finding the right partner to get to market. How can companies analyse and prioritize partner opportunities?